MA35611B1 - Composé inhibiteur de la signalisation par la voie notch - Google Patents
Composé inhibiteur de la signalisation par la voie notchInfo
- Publication number
- MA35611B1 MA35611B1 MA36712A MA36712A MA35611B1 MA 35611 B1 MA35611 B1 MA 35611B1 MA 36712 A MA36712 A MA 36712A MA 36712 A MA36712 A MA 36712A MA 35611 B1 MA35611 B1 MA 35611B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor compound
- signal inhibitor
- notch route
- notch
- route
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005650 Notch Receptors Human genes 0.000 abstract 1
- 108010070047 Notch Receptors Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne un composé, ou un sel ou hydrate pharmaceutiquement acceptable, et une composition pharmaceutique contenant ledit composé, ou sel ou hydrate pharmaceutiquement acceptable, utile en tant qu'inhibiteur de la signalisation par la voie notch pour le traitement du cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512016P | 2011-07-27 | 2011-07-27 | |
| US201161560486P | 2011-11-16 | 2011-11-16 | |
| PCT/US2012/047100 WO2013016081A1 (fr) | 2011-07-27 | 2012-07-18 | Composé inhibiteur de la signalisation par la voie notch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35611B1 true MA35611B1 (fr) | 2014-11-01 |
Family
ID=46598983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36712A MA35611B1 (fr) | 2011-07-27 | 2014-01-22 | Composé inhibiteur de la signalisation par la voie notch |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8569286B2 (fr) |
| EP (1) | EP2736920B1 (fr) |
| JP (1) | JP6027110B2 (fr) |
| KR (1) | KR101578309B1 (fr) |
| CN (1) | CN103732612B (fr) |
| AP (1) | AP4080A (fr) |
| AR (1) | AR087107A1 (fr) |
| AU (1) | AU2012287251B2 (fr) |
| BR (1) | BR112014001600B1 (fr) |
| CA (1) | CA2841178C (fr) |
| CL (1) | CL2014000175A1 (fr) |
| CO (1) | CO6862159A2 (fr) |
| CR (1) | CR20140036A (fr) |
| CY (1) | CY1116645T1 (fr) |
| DK (1) | DK2736920T3 (fr) |
| DO (1) | DOP2014000011A (fr) |
| EA (1) | EA023044B1 (fr) |
| EC (1) | ECSP14013179A (fr) |
| ES (1) | ES2544937T3 (fr) |
| GT (1) | GT201400012A (fr) |
| HR (1) | HRP20150771T1 (fr) |
| HU (1) | HUE027534T2 (fr) |
| IL (1) | IL229988A (fr) |
| JO (1) | JO3148B1 (fr) |
| MA (1) | MA35611B1 (fr) |
| ME (1) | ME02171B (fr) |
| MX (1) | MX356536B (fr) |
| MY (1) | MY184303A (fr) |
| PE (1) | PE20141061A1 (fr) |
| PH (1) | PH12014500215B1 (fr) |
| PL (1) | PL2736920T3 (fr) |
| PT (1) | PT2736920E (fr) |
| RS (1) | RS54135B1 (fr) |
| SI (1) | SI2736920T1 (fr) |
| TW (1) | TWI568730B (fr) |
| WO (1) | WO2013016081A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350216B2 (en) | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| WO2015013579A1 (fr) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions permettant d'améliorer l'avantage thérapeutique du bisantrène |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| AR105080A1 (es) * | 2015-07-07 | 2017-09-06 | Lilly Co Eli | Compuestos inhibidores de la señalización de la vía de notch |
| KR102808827B1 (ko) | 2016-02-05 | 2025-05-19 | 데날리 테라퓨틱스 인크. | 수용체-상호작용 단백질 키나제 1의 억제제 |
| SG11201807965YA (en) | 2016-03-15 | 2018-10-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| US11564929B2 (en) | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
| KR102418765B1 (ko) * | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| MA45025A (fr) | 2016-05-20 | 2019-03-27 | Lilly Co Eli | Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1 |
| CN109562114A (zh) * | 2016-08-31 | 2019-04-02 | 伊莱利利公司 | 用于治疗实体瘤的给药方案 |
| US11376259B2 (en) | 2016-10-12 | 2022-07-05 | Eli Lilly And Company | Targeted treatment of mature T-cell lymphoma |
| DK3552017T3 (da) | 2016-12-09 | 2022-05-16 | Denali Therapeutics Inc | Forbindelser, der er anvendelige som ripk1-inhibitorer |
| BR112019017120A8 (pt) | 2017-02-17 | 2023-05-02 | Hutchinson Fred Cancer Res | Terapias de combinação para tratamento de cânceres e distúrbios autoimunes relacionados a bcma |
| WO2019090003A1 (fr) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Récepteurs d'antigènes chimériques spécifiques de l'antigène de maturation des cellules b (bcma) |
| KR20200099137A (ko) | 2017-11-06 | 2020-08-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법 및 감마 세크레타제 억제제의 조합 |
| KR20210005714A (ko) * | 2018-05-06 | 2021-01-14 | 아얄라 파마큐티컬즈 아이엔씨. | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법 |
| TW202034900A (zh) | 2018-10-02 | 2020-10-01 | 美商頻率醫療公司 | 有關耳用治療劑之醫藥組成物及方法 |
| US20220175776A1 (en) | 2019-04-08 | 2022-06-09 | Frequency Therapeutics, Inc. | Combination of chir99021 and valproic acid for treating hearing loss |
| WO2023137035A1 (fr) | 2022-01-12 | 2023-07-20 | Denali Therapeutics Inc. | Formes cristallines de ((s)-5-benzyl-n-(5-méthyl-4-oxo-2, 3,4,5- tétrahydropyrido [3,2-b] [l,4]oxazépin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP970705A2 (en) * | 1996-12-23 | 1998-10-31 | Warren J. Porter | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
| CA2324474A1 (fr) | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | Composes destines a inhiber la liberation et/ou la synthese du peptide beta-amyloide |
| JP2002518483A (ja) * | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ，インコーポレイテッド | β−アミロイドペプチド放出を阻害するための化合物および／またはその合成 |
| MXPA05008172A (es) | 2003-02-04 | 2005-10-05 | Hoffmann La Roche | Derivados de malonamida como inhibidores gamma-secretasa. |
| KR20070087233A (ko) | 2003-09-09 | 2007-08-27 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| HRP20151197T1 (hr) | 2003-10-06 | 2015-12-04 | F. Hoffmann - La Roche Ag | Supstituirani derivati dibenzo-azepina i benzo-diazepina, koji su korisni kao inhibitori gama-sekretaze |
| KR101169628B1 (ko) | 2006-03-27 | 2012-07-30 | 에프. 호프만-라 로슈 아게 | 감마 세크레테아제 저해제로서의 말론아미드 유도체 |
| JP2010517954A (ja) * | 2007-02-02 | 2010-05-27 | エフ．ホフマン−ラ ロシュ アーゲー | ６−オキソ−６，７−ジヒドロ−５Ｈ−ジベンゾ［ｂ，ｄ］アゼピン−７−イル誘導体 |
| CN101909633B (zh) | 2008-01-11 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | γ-分泌酶抑制剂用于治疗癌症的应用 |
| US8637493B2 (en) * | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
-
2012
- 2012-07-10 AR ARP120102486A patent/AR087107A1/es not_active Application Discontinuation
- 2012-07-10 JO JOP/2012/0190A patent/JO3148B1/ar active
- 2012-07-13 TW TW101125459A patent/TWI568730B/zh active
- 2012-07-18 MY MYPI2014700183A patent/MY184303A/en unknown
- 2012-07-18 CN CN201280037471.9A patent/CN103732612B/zh active Active
- 2012-07-18 SI SI201230246T patent/SI2736920T1/sl unknown
- 2012-07-18 ME MEP-2015-105A patent/ME02171B/me unknown
- 2012-07-18 MX MX2014001084A patent/MX356536B/es active IP Right Grant
- 2012-07-18 RS RS20150496A patent/RS54135B1/sr unknown
- 2012-07-18 HR HRP20150771TT patent/HRP20150771T1/hr unknown
- 2012-07-18 PT PT127411924T patent/PT2736920E/pt unknown
- 2012-07-18 AU AU2012287251A patent/AU2012287251B2/en not_active Ceased
- 2012-07-18 HU HUE12741192A patent/HUE027534T2/en unknown
- 2012-07-18 US US13/551,681 patent/US8569286B2/en active Active
- 2012-07-18 KR KR1020147001731A patent/KR101578309B1/ko active Active
- 2012-07-18 PE PE2014000129A patent/PE20141061A1/es active IP Right Grant
- 2012-07-18 PH PH1/2014/500215A patent/PH12014500215B1/en unknown
- 2012-07-18 DK DK12741192.4T patent/DK2736920T3/en active
- 2012-07-18 EA EA201490161A patent/EA023044B1/ru not_active IP Right Cessation
- 2012-07-18 WO PCT/US2012/047100 patent/WO2013016081A1/fr not_active Ceased
- 2012-07-18 BR BR112014001600-3A patent/BR112014001600B1/pt active IP Right Grant
- 2012-07-18 JP JP2014522877A patent/JP6027110B2/ja active Active
- 2012-07-18 CA CA2841178A patent/CA2841178C/fr active Active
- 2012-07-18 AP AP2014007362A patent/AP4080A/en active
- 2012-07-18 PL PL12741192T patent/PL2736920T3/pl unknown
- 2012-07-18 ES ES12741192.4T patent/ES2544937T3/es active Active
- 2012-07-18 EP EP12741192.4A patent/EP2736920B1/fr active Active
-
2013
- 2013-12-17 IL IL229988A patent/IL229988A/en active IP Right Grant
-
2014
- 2014-01-22 DO DO2014000011A patent/DOP2014000011A/es unknown
- 2014-01-22 MA MA36712A patent/MA35611B1/fr unknown
- 2014-01-23 CL CL2014000175A patent/CL2014000175A1/es unknown
- 2014-01-24 GT GT201400012A patent/GT201400012A/es unknown
- 2014-01-24 CR CR20140036A patent/CR20140036A/es unknown
- 2014-01-24 CO CO14014585A patent/CO6862159A2/es active IP Right Grant
- 2014-01-27 EC ECSP14013179 patent/ECSP14013179A/es unknown
-
2015
- 2015-08-25 CY CY20151100742T patent/CY1116645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35611B1 (fr) | Composé inhibiteur de la signalisation par la voie notch | |
| PH12020551062A1 (en) | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA37888A1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
| MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
| MA38227A1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| MA38472B1 (fr) | Composé peptidique | |
| MA35351B1 (fr) | Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. | |
| EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
| IN2014MN02106A (fr) | ||
| EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
| MA35107B1 (fr) | Composition pharmaceutique antihypertensive | |
| EA201170997A1 (ru) | Производные индола в качестве противораковых агентов | |
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| MA42776B1 (fr) | Composés utiles pour l'inhibition du ror-gamma-t | |
| MA37501B1 (fr) | Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 | |
| UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA30523B1 (fr) | Compose tricylique et utilisation pharmaceutique de celui-ci | |
| MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain |